Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma

被引：19

作者：

Bobin-Dubigeon, C. ^{[1
,2
]}

Amiand, M. B. ^{[1
]}

Herrenknecht, C. ^{[2
]}

Bard, J. M. ^{[1
,2
]}

机构：

[1] CLCC Rene Gauducheau, Dept Oncol Biol, F-44805 St Herblain, France

[2] Univ Nantes, Fac Pharm, EA MMS 2160, F-44000 Nantes, France

来源：

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2009年 / 877卷 / 24期

关键词：

Pemetrexed; Liquid chromatography/mass spectrometry; Plasma; Pharmacokinetic studies; THYMIDYLATE SYNTHASE INHIBITOR; PHASE-II; LY231514; PHARMACOKINETICS; METABOLISM; AGENT;

D O I：

10.1016/j.jchromb.2009.06.020

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

An improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma was developed and validated using a simple quadrupole LC-MS and a new SPE cartridge (Plexa (R) Bond Elut). The analysis was achieved with a C18 analytical column using a mobile phase consisting of formic acid/acetonitrile and isocratic flow for 7 min. The linear ranges (r(2) > 0.99) were found from 5 to 5000 ng/mL. The lower limit of detection was 2.5 ng/mL Within-day and between-day precisions were less than 7.2% and inaccuracy did not exceed 2.8%. This new method is suitable to support pharmacokinetic studies and drug monitoring. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：2451 / 2456

页数：6

共 19 条

[1]

[Anonymous], 1997, STP Pharma Pratiques

[2]

[Anonymous], 2001, Guidance for industry, bioanalytical method validation

[3]

BUNN PA, 2002, SEMIN ONCOL, V20, P1

[4]

CHAUDHARY AK, 1999, P 47 ASMS C MASS SPE

[5] Molecular, biochemical, and cellular pharmacology of pemetrexed [J].

Goldman, ID ;

Zhao, RB .

SEMINARS IN ONCOLOGY, 2002, 29 (06) :3-17

[6] COLUMN-SWITCHING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF A THYMIDYLATE SYNTHASE INHIBITOR, LY231514, AN INVESTIGATIONAL AGENT FOR THE TREATMENT OF SOLID TUMORS, IN HUMAN PLASMA [J].

HAMILTON, CL ;

KIRKWOOD, JA .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1994, 654 (02) :297-303

[7] Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma [J].

Hughes, A ;

Calvert, P ;

Azzabi, A ;

Plummer, R ;

Johnson, R ;

Rusthoven, J ;

Griffin, M ;

Fishwick, K ;

Boddy, AV ;

Verrill, M ;

Calvert, H .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3533-3544

[8]

Lansiaux A, 2007, B CANCER, V94, pS134

[9] Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients [J].

Latz, JE ;

Chaudhary, A ;

Ghosh, A ;

Johnson, RD .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (04) :401-411

[10] Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules [J].

Li, K. M. ;

Rivory, L. P. ;

Clarke, S. J. .

BRITISH JOURNAL OF CANCER, 2007, 97 (08) :1071-1076

← 1 2 →